Ultimovacs ASA
OSE:ULTI.OL
107.4 (NOK) • At close November 17, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) NOK.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 2.768 | 2.648 | 2.703 | 2.72 | 2.063 | 0.601 | 0.534 | 0.489 |
| Gross Profit
| -2.768 | -2.648 | -2.703 | -2.72 | -2.063 | -0.601 | -0.534 | -0.489 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 123.834 | 95.175 | 96.735 | 64.66 | 35.528 | 16.957 | 12.829 | 12.139 |
| General & Administrative Expenses
| 0 | 9.246 | 5.061 | 3.978 | 3.658 | 6.641 | 0.397 | 0.505 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 99.339 | 9.246 | 5.061 | 3.978 | 3.658 | 6.641 | 0.397 | 0.505 |
| Other Expenses
| 0 | 79.209 | 62.036 | 55.508 | 27.032 | 32.925 | 20.165 | 16.54 |
| Operating Expenses
| 223.173 | 183.63 | 163.832 | 124.146 | 66.218 | 56.523 | 33.391 | 29.184 |
| Operating Income
| -225.941 | -183.631 | -163.832 | -124.146 | -61.6 | -56.522 | -33.391 | -29.183 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 36.702 | 15.839 | -0.89 | 3.594 | 0.434 | 1.242 | 0.561 | 0.203 |
| Income Before Tax
| -189.239 | -167.792 | -164.722 | -120.552 | -61.166 | -55.28 | -32.83 | -28.98 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | -20.891 | 2.035 | -3.834 | -5.315 | -1.376 | -0.561 | -0.204 |
| Net Income
| -189.239 | -146.901 | -166.757 | -116.718 | -55.851 | -53.904 | -32.269 | -28.776 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -5.5 | -4.29 | -5.15 | -3.86 | -2.44 | -3.36 | -2.09 | -1.86 |
| EPS Diluted
| -5.5 | -4.29 | -5.15 | -3.86 | -2.44 | -3.36 | -2.09 | -1.86 |
| EBITDA
| -223.173 | -186.035 | -159.651 | -121.426 | -64.155 | -55.922 | -32.857 | -28.695 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |